

Special Issue

Personalized Medicine in Lung Cancer: Diagnosis, Treatment and Prognosis

Message from the Guest Editor

Lung cancer is the most common cause of cancer-related mortality worldwide. Although new therapeutic strategies are defined according to the molecular profile of the tissue, a high rate of these targeted therapies fail to cure the disease because of several biological and technological challenges, mainly the heterogeneity of the tumor. The purpose of this Special Issue, *Personalized Medicine in Lung Cancer: Diagnosis, Treatment and Prognosis*, is to highlight: 1) the benefit of personalized medicine in the diagnosis, treatment, and prognosis of lung cancer patients; 2) the new assays that could achieve high sensitivity for early detection of minimal residual disease (MRD) in lung cancer patients; 3) the crucial role of liquid biopsies in personalized medicine in lung cancer; and 4) the spatial heterogeneity as well as temporal heterogeneity between the primary tumor and local or distant recurrences in the same patient. Finally, we also wish to present the rapid development of technology and drugs in this area of research.

Guest Editor

Dr. Athina N. Markou

Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece

Deadline for manuscript submissions

closed (31 March 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/95252

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).